Arcutis Biotherapeutics has launched a consumer awareness campaign called “Skin to Believe,” with Olympic gymnast Simone Biles serving as its public face, Drug Store News reports.

The campaign name and the choice of Biles signal a consumer-directed effort rather than a clinical data announcement. Arcutis has built its commercial portfolio around topical treatments for inflammatory skin disease, and patient-facing campaigns of this type typically aim to reduce stigma around visible dermatologic conditions and to drive patients toward treatment conversations with prescribers.

What the announcement establishes concretely is limited but notable: a publicly traded dermatology company has secured one of the most recognizable athletes in the United States as a campaign figurehead. Biles, an eleven-time Olympic medalist, brings reach well beyond the typical dermatology patient audience — a pattern increasingly common as pharmaceutical brands compete for attention in crowded topical and biologic markets.

The headline does not specify which Arcutis product or condition the campaign supports, nor does it detail campaign timing, media channels, or any accompanying disease-awareness metrics. Drug Store News’ report names the campaign and its star; deeper specifics — formulation, indication, or claims language — were not included in the item as distributed.

For dermatology clinicians and practice staff, the relevance is indirect but real. Consumer campaigns featuring high-profile figures reliably increase patient inquiry volume: patients arrive asking whether a marketed therapy fits their diagnosis. Practices treating plaque psoriasis, seborrheic dermatitis, or atopic dermatitis — the indications around which Arcutis has concentrated its development — may see heightened questions tied to the campaign.

The development also fits a broader industry shift. Dermatology manufacturers increasingly pair prescription launches with celebrity-driven awareness work, betting that destigmatization and name recognition accelerate diagnosis and treatment initiation in categories where patients often self-manage or disengage.

Whether “Skin to Believe” translates into measurable patient action will depend on details — target indication, media spend, and any screening or telehealth pathways attached to the campaign — that the announcement did not specify. Clinicians and industry watchers should expect Arcutis to publish those parameters as the campaign rolls out.